Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo
José Á. Morales-García(Universitat de Vic - Universitat Central de Catalunya), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Carmen Gil(Instituto de Salud Carlos III), Marina Sanz-SanCristóbal(Biomedical Research Networking Center on Neurodegenerative Diseases), Rosario Luna‐Medina(Consejo Superior de Investigaciones Científicas), Ángel Santos(Universidad Complutense de Madrid), Sandra Alonso‐Gil(Biomedical Research Networking Center on Neurodegenerative Diseases), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 159
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293